Shanghai Haoyuan Chemexpress Co., Ltd.

SHSE:688131 Stock Report

Market Cap: CN¥7.1b

Shanghai Haoyuan Chemexpress Past Earnings Performance

Past criteria checks 1/6

Shanghai Haoyuan Chemexpress's earnings have been declining at an average annual rate of -1%, while the Life Sciences industry saw earnings growing at 19.5% annually. Revenues have been growing at an average rate of 30.5% per year. Shanghai Haoyuan Chemexpress's return on equity is 3.8%, and it has net margins of 5%.

Key information

-1.0%

Earnings growth rate

-9.1%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate30.5%
Return on equity3.8%
Net Margin5.0%
Next Earnings Update30 Oct 2024

Recent past performance updates

Earnings Troubles May Signal Larger Issues for Shanghai Haoyuan Chemexpress (SHSE:688131) Shareholders

May 06
Earnings Troubles May Signal Larger Issues for Shanghai Haoyuan Chemexpress (SHSE:688131) Shareholders

Recent updates

Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) 25% Jump Shows Its Popularity With Investors

Sep 19
Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) 25% Jump Shows Its Popularity With Investors

Investors Appear Satisfied With Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) Prospects

Jul 13
Investors Appear Satisfied With Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) Prospects

Shanghai Haoyuan Chemexpress (SHSE:688131) Has A Somewhat Strained Balance Sheet

Jun 13
Shanghai Haoyuan Chemexpress (SHSE:688131) Has A Somewhat Strained Balance Sheet

Earnings Troubles May Signal Larger Issues for Shanghai Haoyuan Chemexpress (SHSE:688131) Shareholders

May 06
Earnings Troubles May Signal Larger Issues for Shanghai Haoyuan Chemexpress (SHSE:688131) Shareholders

After Leaping 27% Shanghai Haoyuan Chemexpress Co., Ltd. (SHSE:688131) Shares Are Not Flying Under The Radar

Mar 20
After Leaping 27% Shanghai Haoyuan Chemexpress Co., Ltd. (SHSE:688131) Shares Are Not Flying Under The Radar

Revenue & Expenses Breakdown

How Shanghai Haoyuan Chemexpress makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688131 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 242,055103424228
31 Mar 241,96798404227
31 Dec 231,880127389224
30 Sep 231,764154384232
30 Jun 231,618172350227
31 Mar 231,476178319219
31 Dec 221,358194290202
30 Sep 221,243205259176
30 Jun 221,135212235143
31 Mar 221,044199217119
31 Dec 21969191188103
30 Sep 2191820215187
30 Jun 2184117814179
31 Mar 2173616012169
31 Dec 2063512811765
31 Dec 19409739053
31 Dec 18300188835
30 Jun 1715031460
31 Mar 1713424410
31 Dec 1611718370
30 Sep 1611618330
30 Jun 169611240
31 Mar 169410220
31 Dec 15929200
31 Dec 14673150
31 Dec 13592120

Quality Earnings: 688131 has high quality earnings.

Growing Profit Margin: 688131's current net profit margins (5%) are lower than last year (10.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688131's earnings have declined by 1% per year over the past 5 years.

Accelerating Growth: 688131's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 688131 had negative earnings growth (-40.2%) over the past year, making it difficult to compare to the Life Sciences industry average (-7.5%).


Return on Equity

High ROE: 688131's Return on Equity (3.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies